ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,505,409 shares, an increase of 46.5% from the November 30th total of 1,709,714 shares. Approximately 7.1% of the shares of the company are sold short. Based on an average trading volume of 8,471,839 shares, the days-to-cover ratio is currently 0.3 days.

ImmunoCellular Therapeutics (IMUC) opened at $0.31 on Friday. ImmunoCellular Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $4.27. The company has a market cap of $6.66, a P/E ratio of -0.10 and a beta of 1.04.

TRADEMARK VIOLATION NOTICE: “ImmunoCellular Therapeutics Ltd (IMUC) Sees Significant Growth in Short Interest” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/12/30/immunocellular-therapeutics-ltd-imuc-sees-significant-growth-in-short-interest.html.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.